The inhibition of PDEs, primarily PDE5, has been shown to be effective in preclinical models of cancer by inhibiting important pathways, such as the MAPK and JNK pathways, that influence the growth and death of cancer cells and metastasis. This evidence concerns the gene PDE5A and cancer.